Subgroup analysis of OAK trial data supports use of atezolizumab in patients with NSCLC

Shirish Gadgeel, MD of the Barbara Ann Karmanos Cancer Institute at Wayne State University in Detroit, presented new analysis results in specific subgroups of patients enrolled in the OAK trial. OAK was the first randomized Phase III study evaluating an anti-PDL1 antibody (atezolizumab) in the management of advanced non-small cell lung cancer (NSCLC).
The subgroup analysis presented by Dr Gadgeel evaluated the efficacy of atezolizumab compared to docetaxel in a variety of clinically-relevant subgroups of NSCLC based on PDL-1 gene expression, central nervous system (CNS) metastasis, history of smoking, and patient age.
The results presented by Dr Gadgeel showed that atezolizumab improves survival compared to docetaxel in all these subgroups. It also showed effects in certain subgroups such as never-smokers where previous PD-1-directed agents did not show effects, warranting further investigation into possible differences in activity between PD-1- and PD-L1-directed antibodies.

Recorded at the 2016 World Congress of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.

Share this video